MindRank

AI-Powered Small Molecule Drug Discovery

Shanghai, China · Founded 2021 · $82.0M raised

Headquarters
Shanghai
Employees
11–50
Founded
2021
Business Model
B2B
Total Funding
$82.0M
Last Round
$52.0M Series BJul 2026
Rounds
4

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

MindRank is an AI-powered small-molecule drug discovery company that integrates innovations in machine learning, biology, and chemistry to advance drug discovery against hard-to-drug molecular targets. Its proprietary Molecule Pro platform is designed to accelerate drug discovery and deliver small-molecule drugs with superior potency, druggability, and novelty. MindRank's AI-designed proprietary drug MDR-001, an oral small-molecule GLP-1 receptor agonist, obtained US IND approval within 19 months of program initiation for treatment of obesity and type 2 diabetes, and has entered Phase III clinical trials. The company, comprising more than 40 scientists including top biopharma experts and global AI competition winners, was named to Forbes Asia's 2023 '100 to Watch' list and partners with Roche Accelerator to advance AI-native drug discovery.

Summary

MindRank is an Artificial Intelligence company based in Shanghai, China, founded in 2021. It has raised $82.0M in total across 4 rounds, most recently a $52.0M Series B round in Jul 2026. Investors include Sherpa Healthcare Partners.

Funding History

Series BSeries BJul 2026
$52.0M

Sign up to see all 4 events

Funding: Seed through Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

MindRank on Indexed.vc
<a href="https://indexed.vc/companies/mindrank-ai"><img src="https://indexed.vc/api/badge/company/mindrank-ai" alt="MindRank on Indexed.vc" width="260" height="76" /></a>